OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
-20.34%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$268M
AUM Growth
+$268M
(-32%)
Cap. Flow
-$30.8M
Cap. Flow
% of AUM
-11.49%
Top 10 Holdings %
Top 10 Hldgs %
57.14%
Holding
61
New
14
Increased
11
Reduced
11
Closed
14
Top Buys
| 1 |
Avalo Therapeutics
AVTX
|
$6.21M |
| 2 |
EPZM
Epizyme, Inc
EPZM
|
$5.7M |
| 3 |
IMGN
Immunogen Inc
IMGN
|
$4.9M |
| 4 |
AIMT
Aimmune Therapeutics, Inc.
AIMT
|
$3.59M |
| 5 |
Abeona Therapeutics
ABEO
|
$3.21M |
Top Sells
| 1 |
Agios Pharmaceuticals
AGIO
|
$10M |
| 2 |
AMAG
AMAG Pharmaceuticals, Inc.
AMAG
|
$8.4M |
| 3 |
Xenon Pharmaceuticals
XENE
|
$7.01M |
| 4 |
Ultragenyx Pharmaceutical
RARE
|
$6.11M |
| 5 |
Ocular Therapeutix
OCUL
|
$5.5M |
Sector Composition
| 1 | Healthcare | 98.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Codexis
CDXS
$246M
| $29.2M | 10.91% | 1,750,000 | – | – |
|
2
Axogen
AXGN
$743M
| $26.6M | 9.91% | 1,300,000 | – | – |
|
|
LOXO
3
DELISTED
Loxo Oncology, Inc
LOXO
| $24.5M | 9.15% | 175,000 | – | – |
|
|
AMRN
4
Amarin Corp
AMRN
$311M
| $17M | 6.35% | 1,250,000 -350,000 | -22% | -$4.76M |
|
|
BPMC
5
DELISTED
Blueprint Medicines
BPMC
| $16.2M | 6.04% | 300,000 | – | – |
|
6
Harrow
HROW
$1.44B
| $9.8M | 3.66% | 1,722,000 +102,000 | +6% | +$580K |
|
7
FibroGen
FGEN
$47.8M
| $9.26M | 3.45% | 200,000 | – | – |
|
|
DCPH
8
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $7.14M | 2.66% | 340,000 -80,000 | -19% | -$1.68M |
|
|
EPZM
9
DELISTED
Epizyme, Inc
EPZM
| $6.93M | 2.59% | 1,125,000 +925,000 | +463% | +$5.7M |
|
10
PTC Therapeutics
PTCT
$3.92B
| $6.52M | 2.43% | 190,000 +10,000 | +6% | +$343K |
|
11
Xencor
XNCR
$580M
| $6.51M | 2.43% | 180,000 | – | – |
|
12
Viking Therapeutics
VKTX
$3.04B
| $6.31M | 2.36% | 825,000 | – | – |
|
|
SBBP
13
DELISTED
Strongbridge Biopharma plc.
SBBP
| $6.23M | 2.32% | 1,390,000 -340,000 | -20% | -$1.52M |
|
|
14
Avalo Therapeutics
AVTX
$122M
| $6.21M | 2.32% | +2,185,536 | New | +$6.21M |
|
15
Fennec Pharmaceuticals
FENC
$247M
| $5.74M | 2.14% | 900,000 -75,000 | -8% | -$479K |
|
16
Sangamo Therapeutics
SGMO
$157M
| $5.74M | 2.14% | 500,000 +10,000 | +2% | +$115K |
|
|
CBAY
17
DELISTED
Cymabay Therapeutics
CBAY
| $5.71M | 2.13% | 725,000 +26,900 | +4% | +$212K |
|
|
PTE
18
DELISTED
PolarityTE, Inc. Common Stock
PTE
| $5.4M | 2.01% | 400,000 -365,000 | -48% | -$4.92M |
|
|
BOLD
19
DELISTED
Audentes Therapeutics, Inc
BOLD
| $5.33M | 1.99% | 250,000 +25,000 | +11% | +$533K |
|
|
CMRX
20
DELISTED
Chimerix, Inc.
CMRX
| $5.19M | 1.94% | 2,020,000 +835,000 | +70% | +$2.15M |
|
21
Xoma
XOMA
$392M
| $5.06M | 1.89% | 400,000 +80,000 | +25% | +$1.01M |
|
|
IMGN
22
DELISTED
Immunogen Inc
IMGN
| $4.9M | 1.83% | +1,021,000 | New | +$4.9M |
|
23
Apellis Pharmaceuticals
APLS
$3.48B
| $3.63M | 1.35% | 275,000 -100,000 | -27% | -$1.32M |
|
|
AIMT
24
DELISTED
Aimmune Therapeutics, Inc.
AIMT
| $3.59M | 1.34% | +150,000 | New | +$3.59M |
|
|
25
Abeona Therapeutics
ABEO
$350M
| $3.21M | 1.2% | +450,000 | New | +$3.21M |
|